KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Return on Sales (2017 - 2025)

Historic Return on Sales for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 1.21%.

  • Aquestive Therapeutics' Return on Sales fell 3600.0% to 1.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.24%, marking a year-over-year increase of 58400.0%. This contributed to the annual value of 43.79% for FY2024, which is 436300.0% down from last year.
  • Per Aquestive Therapeutics' latest filing, its Return on Sales stood at 1.21% for Q3 2025, which was down 3600.0% from 1.35% recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Return on Sales ranged from a high of 0.72% in Q1 2023 and a low of 6.18% during Q2 2021
  • Moreover, its 5-year median value for Return on Sales was 1.09% (2022), whereas its average is 1.29%.
  • As far as peak fluctuations go, Aquestive Therapeutics' Return on Sales soared by 41500bps in 2022, and later crashed by -17900bps in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Return on Sales (Quarter) stood at 2.61% in 2021, then soared by 56bps to 1.16% in 2022, then skyrocketed by 47bps to 0.61% in 2023, then soared by 162bps to 0.38% in 2024, then plummeted by -416bps to 1.21% in 2025.
  • Its Return on Sales stands at 1.21% for Q3 2025, versus 1.35% for Q2 2025 and 2.63% for Q1 2025.